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Bone mineral density and nutritional status in
children with chronic inflammatory bowel disease
A M Boot, J Bouquet, E P Krenning, S M P F de Muinck Keizer-Schrama
Abstract
Background—Osteoporosis has been re-
ported in adult patients with inflamma-
tory bowel disease.
Aims—To evaluate bone mineral density
(BMD), nutritional status, and determi-
nants of BMD in children with inflamma-
tory bowel disease.
Patients—Fifty five patients (34 boys and
21 girls, age range 4–18) were studied; 22
had Crohn’s disease and 33 ulcerative
colitis.
Methods—Lumbar spine and total body
BMD, and body composition were as-
sessed by dual energy x ray absorptiom-
etry (DXA). Results were expressed as
standard deviation scores (SDS). Lean
body mass was also assessed by bioelectri-
cal impedance analysis (BIA). Yearly
measurements during two years were per-
formed in 21 patients.
Results—The mean SDS of lumbar spine
BMD and total body BMD were signifi-
cantly lower than normal (−0.75 and
−0.95, both p<0.001). Height SDS and
body mass index SDS were also de-
creased. The decrease in BMD SDS could
not be explained by delay in bone matura-
tion. The cumulative dose of prednisolone
correlated negatively with lumbar spine
BMD SDS (r=−0.32, p<0.02). Body mass
index SDS correlated positively with total
body BMD SDS (r=0.36, p<0.02). Patients
with Crohn’s disease had significantly
lower lumbar spine and total body BMD
SDS than patients with ulcerative colitis,
even after adjustment for cumulative dose
of prednisolone. In the longitudinal data
cumulative dose of prednisolone between
the measurements correlated negatively
with the change in lumbar spine and total
body BMD SDS. Lean tissue mass meas-
ured by DXA had a strong correlation
with lean body mass measured by BIA
(r=0.98).
Conclusions—Children with inflamma-
tory bowel disease have a decreased BMD.
Children with Crohn’s disease have a
higher risk of developing osteopaenia than
children with ulcerative colitis. Cortico-
steroid therapy and nutritional status are
important determinants of BMD in these
patients.
(Gut 1998;42:188–194)
Keywords: bone mineral density; inflammatory bowel
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Several studies have reported an increased
prevalence of osteoporosis in adult patients
with chronic inflammatory bowel disease
(IBD).1–4 An increased rate of spinal bone loss
was found in 54% of adult patients with IBD.5
Retardation of growth and skeletal matura-
tion are common in children with IBD.6 7 A
study of children with Crohn’s disease reported
decreased bone mass of the distal radius,
measured with single photon absorptiometry.8
Two other studies reported low bone mineral
density (BMD) in children with IBD.9 10
Children with osteopaenia have a higher risk of
fractures in childhood and also in adulthood
because of not reaching their optimal peak
bone mass.
In recent years it has been possible to meas-
ure BMD quantitatively by dual energy x ray
absorptiometry (DXA), which, due to its short
scan time and low radiation dose, is suitable for
use in children.11 With the total body
measurement, body composition in lean tissue
mass, fat mass, and bone mineral content are
assessed.
In the present study, using cross sectional
and longitudinal data, we investigated the
prevalence of and risk factors for a low BMD in
children and adolescents with Crohn’s disease
or ulcerative colitis. The results of body
composition measurements by DXA were
compared with those obtained by bioelectrical
impedance analysis.
Patients and methods
PATIENTS
Fifty five patients (34 boys and 21 girls) with
chronic inflammatory disease were studied.
Twenty two patients had Crohn’s disease and
33 had ulcerative colitis. Diagnosis was made
according to the Dutch children’s IBD consen-
sus guidelines.12 The mean age was 13 years
(range 4–18 years). Thirty six patients were
studied prospectively. The intervals between
DXA measurements were about one year.
Thirty six patients were followed for a period of
one year, and 21 for a period of two years.
Fourteen patients had Crohn’s disease of the
small bowel, four of the colon, and four of both.
Five patients underwent an ileocaecal resection
before the first measurement. Two patients
with ulcerative colitis also had sclerosing
pericholangitis and one also had ulcerative
colitis from chronic active hepatitis. The dura-
tion of the symptoms of the disease ranged
from one month to 12 years (median duration
2.2 years).
The total lifetime cumulative dose of pred-
nisolone (in mg) was calculated at the first
measurement and also the cumulative dose
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between the yearly measurements. Twenty
patients (36%) had not been treated with cor-
ticosteroids before the first measurement.
Three of these received corticosteroids before
the second measurement. All patients had been
treated with sulphasalazine or mesalazine.
METHODS
Height was measured with a Harpenden stadi-
ometer. Height was compared to age and sex
matched reference values13 and expressed as
standard deviation scores (SDS). Weight was
assessed by a standard clinical balance. The
body mass index was calculated as weight/
height2 (kg/m2), compared to age and sex
matched reference values,14 and expressed as
SDS.
Pubertal development was determined ac-
cording to Tanner.15 For patients in puberty,
delay in puberty was calculated by comparison
of Tanner stage and age of the patients with
reference data of Dutch children.13 The delay
was calculated as the diVerence between the
age of the patient and the median age of the
next Tanner stage of the reference group.
BMD of the lumbar spine and total body was
measured by DXA (Lunar,DPXL/PED,Lunar
Radiation Corporation, Madison, Wisconson,
USA). The coeYcient of variation has been
reported as 1.04% for lumbar spine and 0.64%
for total body.16 The coeYcient of variation was
1.1% (SD 0.2) in our setting. BMD results
were compared to our age and sex matched
Dutch reference values (n=500)17 and ex-
pressed as SDS. Patients with a BMD SDS
below −1.5 were given supplements of calcium
500 mg per day and vitamin D 400 units per
day.
With the total body measurement by DXA
the body composition was measured as lean
tissue mass, fat mass, and bone mineral
content. Total tissue mass is the sum of these
three variables. Percentage body fat is given for
total tissue mass. The coeYcients of variation
have been reported as 2.2% for fat mass, 1.1%
for lean tissue mass, and 0.6% for bone mineral
content.16 Bone mineral content, lean tissue
mass, fat mass, and percentage body fat were
compared to our age and sex matched Dutch
reference values and expressed as SDS.18
Lean body mass was also estimated with
bioelectrical impedance analysis (BIA 101,RJL
Systems, Detroit, Michigan). Two skin elec-
trodes were placed on the dorsal surface of the
left hand and wrist, and two electrodes on the
surface of the left foot and ankle joint, accord-
ing to the standard procedure as described
previously.19 Whole body resistance and reac-
tance were measured. With these values and
also age, sex, weight, and height, the lean body
mass was calculated by a programme provided
by the manufacturer with separate pro-
grammes for children (4–12 years), adolescents
(13–16 years), and adults (17 years and older).
A total of 103 measurements with BIA were
compared to simultaneous DXA measure-
ments. No oedema was present in any of the
patients.
Dietary calcium intake and total caloric
intake were assessed in 36 patients by a
dietitian using a three day food intake diary.
The results were compared to the recom-
mended Dutch intake of calcium and calories
with respect to sex and age group.
During an interview children above 10 years
of age were asked about their daily habitual
physical activity,20 which included physical
education classes, organised sports, recrea-
tional activity, and habitual walking and
cycling. The results were compared to the
healthy controls of the BMD reference popula-
tion in which the same questionnaire was
used.17
Bone age was assessed in 52 children by one
investigator (AB) using an x ray of the left hand
according to the Tanner-Whitehouse radius-
ulna-short bones (RUS method).21 Two x rays
of the hand were taken in 30 patients and three
x rays in 14 patients with intervals of about one
year.
Blood samples were taken at the first
measurement for the assessment of calcium,
phosphate, alkaline phosphatase, parathyroid
hormone, 25-hydroxyvitamin D, 1,25-
dihydroxyvitamin D, osteocalcin, the carboxy
terminal propeptide of type I collagen (PICP),
and insulin like growth factor I (IGF-I). Serum
intact parathyroid hormone was determined in
21 patients by radioimmunoassay (Nichols
Institute, San Juan Capistrano, California,
USA). 25-Hydroxyvitamin D was assessed in
42 patients and 1,25-dihydroxyvitamin D in 23
patients. The following were measured by
radioimmunoassay: osteocalcin and 25-
hydroxyvitamin D (Incstar Corporation, Still-
water, USA), 1,25-dihydroxyvitamin D (Im-
muno Diagnostic Systems, Boldon, UK), and
PICP (Orion Diagnostica, Espoo, Finland).
Osteocalcin was assessed in 41 patients and
PICP in 39 patients. Our own reference values
for osteocalcin and PICP (n=25 and n=82
respectively) were used for prepubertal chil-
dren. Reference values for the older children
were taken from other studies which used the
same assay methods.22–24 For measurements of
IGF-I, kits from Med-Genix Diagnostics,
Fleurus, Belgium, were used. IGF-I was
assessed in 50 patients. IGF-I sex and age
matched reference values were based on 600
samples of a healthy Dutch population.25 The
ratio of hydroxyproline and creatinine was
evaluated in 24 hour urine in 47 patients and
compared to reference values.26
STATISTICS
One sample t tests were performed to compare
the mean SDS values to normal values. Two
sample t tests were used to compare variables
with a normal distribution between two
groups. The Pearson correlation coeYcient
was calculated to test the association between
two variables with a normal distribution.
Spearman’s rank correlation coeYcient was
utilised in case of a non-normal distribution.
Multiple regression analysis was used for
adjustment of confounders and to test possible
pathogenic factors of osteopaenia simultane-
ously. One way analysis of variance was
performed to test diVerences in more than two
groups.
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Results
Mean SDS of the lumbar spine BMD at the
first measurement was −0.75 (SD 1.20), and of
total body BMD −0.95 (1.22); both values
were significantly lower than reference values
(p<0.001). Four patients (7%), of whom one
had not been treated with corticosteroids, had
lumbar spine BMD SDS below −2 and eight
patients (15%), of whom three had not used
corticosteroids before, had total body BMD
SDS below −2. Figure 1 shows the BMD
results. Mean BMD SDS of boys was not
significantly diVerent from that of girls. None
of the patients experienced a fracture during
the study period.
The mean delay in bone maturation
(chronological age minus bone age) was 0.71
years (SD 1.63). If the BMD SDS was
calculated for bone age instead of chronologi-
cal age, the mean lumbar spine BMD SDS was
−0.47 (1.04) and total body BMD SDS −0.80
(1.04), both still significantly below zero
(p<0.01 and p<0.001 respectively). The delay
in bone maturation had a significant negative
correlation with lumbar spine BMD SDS
(r=−0.47, p<0.001) and total body BMD SDS
Figure 1 Lumbar spine and total body BMD results of the first measurement in 55 patients with IBD. The continuous line represents the mean of
reference values, the dotted lines +2 and −2 SD.
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(r=−0.45, p<0.001). The mean delay of
puberty was 0.70 years (1.14). A greater delay
related to lower lumbar spine BMD SDS
(r=−0.45, p<0.01) and total body BMD SDS
(r=−0.54, p<0.001).
The mean height SDS was −0.54 (SD 1.25)
and body mass index SDS −0.66 (0.85), both
significantly below zero (p<0.01 and p<0.001
respectively). Table 1 lists correlations of
various variables with BMD SDS. The correla-
tion coeYcients are similar for Crohn’s disease
and ulcerative colitis.
The total lifetime cumulative dose of pred-
nisolone until the first measurement (median
dose 1.68 g, range 0–35) had a significant
negative association with lumbar spine BMD
SDS but not with total body BMD SDS.
The children with Crohn’s disease had
significantly lower lumbar spine and total body
BMD SDS and height SDS than children with
ulcerative colitis (p=0.01 for lumbar spine and
p=0.003 for total body and height), even after
adjustment for cumulative dose of pred-
nisolone.
The mean physical activity was 8.3 hours per
week (SD 4.6) for boys and 5.9 hours per week
(3.1) for girls, both not significantly diVerent
from controls (9.2 and 7.1 hours per week
respectively). We found no correlation between
physical activity and lumbar spine or total body
BMD SDS.
Lumbar spine or total body BMD SDS did
not diVer between patients who had had a pre-
vious ileocaecal resection and patients who had
had no resection.
The duration of the disease did not relate to
lumbar spine or total body BMD SDS.
In multiple regression analysis with diagno-
sis (Crohn’s disease/ulcerative colitis), cumula-
tive dose of prednisolone and body mass index
SDS as determinants and BMD SDS as
dependent variable, cumulative dose of pred-
nisolone and diagnosis related significantly to
lumbar spine BMD SDS and explained 20% of
the variance. Only diagnosis related signifi-
cantly to total body BMD SDS in this
regression model (r2=15%).
BODY COMPOSITION AND CALORIC AND CALCIUM
INTAKE
The mean SDS of lean tissue mass was −1.04
(SD 1.41), of bone mineral content −1.05
(1.27), of fat mass −0.64 (1.02), and of
percentage body fat −0.38 (1.11); all were sig-
nificantly lower than normal (all p<0.001,
except for percentage body fat p<0.02). Table
1 shows correlations of these variables with
BMD SDS. The SDS of percentage body fat
had no significant correlation with BMD SDS.
Cumulative dose of prednisolone did not relate
to lean body mass SDS or fat mass SDS.
Patients with Crohn’s disease had significantly
lower lean body mass SDS (p=0.003) than
patients with ulcerative colitis. They did not
diVer in fat mass or percentage fat SDS.
The percentage caloric intake of the recom-
mended daily allowance of the 36 children,
whose food intake was analysed, varied from
49% to 130% (mean 92%). Seventeen children
(47%) had a caloric intake more than 10%
below the recommended daily allowance. Five
children (14%) had a low calcium intake.
BIOCHEMICAL PARAMETERS OF BONE METABOLISM
Five children had decreased 25-hydroxy-
vitamin D levels and one child a low 1,25-
dihydroxyvitamin D level. The 25-
hydroxyvitamin D and 1,25-dihydroxyvitamin
D levels did not diVer between patients with
Crohn’s disease and patients with ulcerative
colitis. Osteocalcin was decreased in 3/40
patients (8%) and IGF-I in 11/50 patients
(22%). All patients had normal PICP values.
The patients with a low osteocalcin or a low
IGF-I did not diVer significantly in lumbar
spine or total body BMD SDS, height SDS,
and body mass index SDS from the other
patients. The hydroxyproline:creatinine ratio
was low in 18/47 children (38%), normal in 26
(55%), and high in three (6%). There was a
significant diVerence in lumbar spine and total
body BMD SDS between the patients with a
low, normal, and high hydroxyproline:creati-
nine ratio (both p<0.05). If the ratio was higher
the BMD SDS was lower. The other biochemi-
cal results were within normal limits.
LONGITUDINAL DATA
There was no significant change in BMD SDS
between measurements 1 and 2 (ÄSDS1). The
mean ÄSDS1 of lumbar spine BMD between
the first two measurements was −0.07 (SD
0.48) and of total body BMD 0.06 (SD 0.51).
The ÄSDS1 of lumbar spine and total body
BMD was not significantly correlated with the
cumulative dose of prednisolone between the
measurements (median dose 0.56 g, range
0–5.9 g). Eleven of the 36 patients had received
calcium and vitamin D treatment.
Between measurements 2 and 3 there was a
significant increase in BMD SDS (ÄSDS2).
The mean ÄSDS2 of lumbar spine BMD was
Table 1 Correlation coeYcients of various variables with lumbar spine and total BMD SDS in all 55 children with
inflammatory bowel disease, and separately in the patients with Crohn’s disease (CD; n=22) and ulcerative colitis (UC;
n=33)
Lumbar spine BMD SDS Total body BMD SDS
All CD UC All CD UC
Height SDS 0.54*** 0.18 0.59*** 0.59*** 0.39 0.56***
BMI SDS 0.19 0.11 0.05 0.35** 0.47* 0.14
Cumulative dose of
prednisolone (mg) −0.32** −0.40 −0.35* −0.19 −0.26 −0.22
Lean tissue mass SDS 0.56*** 0.35 0.58*** 0.61*** 0.58** 0.52**
Fat mass SDS 0.08 −0.14 0.04 0.31* 0.10 0.29
*p < 0.05, **p < 0.01, ***p < 0.001.
BMI, body mass index.
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0.46 (SD 0.73), and of total body BMD 0.61
(SD 0.48), both significantly higher than zero
(p<0.02 for lumbar spine and p<0.001 for total
body). The ÄSDS2 of lumbar spine and total
body BMD had a significant negative correla-
tion with the cumulative dose of prednisolone
between measurements 2 and 3 (r=−0.60 for
lumbar spine and r=−0.56 for total body, both
p<0.01). Median cumulative dose between the
measurements was 0.34 g (range 0–4.6 g). Six
of the 21 patients had received calcium and
vitamin D treatment.
There was no significant change in SDS of
the diVerent body composition compartments,
height SDS, body mass index SDS, and delay
in bone maturation between measurements 1
and 2 and between measurements 2 and 3.
COMPARISON BETWEEN DXA AND BIA
There was a high correlation between lean tis-
sue mass measured by DXA and lean body
mass measured by BIA (r=0.98) (fig 2A). The
mean diVerence between DXA lean tissue
mass and BIA lean body mass was 0.94 kg. The
limits of agreements (−2 to +2 SD of the
diVerence) were −4.0 to 5.9 kg (fig 2B). If
DXA lean body mass was calculated as lean
tissue mass plus bone mass, the mean diVer-
ence with BIA lean body mass was higher (2.8
kg, limits of agreement −3.9 to 8.0 kg).
Discussion
Bone mineralisation was reduced in children
and adolescents with IBD. BMD of lumbar
spine as well as of total body were significantly
lower than reference values. Both trabecular
bone, present mainly in lumbar spine, and cor-
tical bone, 80% of the total skeleton,27 were
aVected.
Putative pathogenic factors of osteopenia
have been reported as inflammatory activity,28
steroid therapy,1 malnutrition,1 malabsorp-
tion,29 reduced calcium intake, and vitamin D
deficiency.30
Children with Crohn’s disease had lower
values of lumbar spine and total body BMD
than children with ulcerative colitis. This is in
agreement with Compston et al1 who reported
that 41% of adult patients with Crohn’s disease
had decreased bone mass in contrast to only
14% of patients with ulcerative colitis. Other
studies reported low BMD in patients with
Crohn’s disease but not in patients with
ulcerative colitis.4 29 Osteopaenia and growth
failure in children have been reported to be
more severe in children with Crohn’s disease
than in children with ulcerative colitis.9 10 31 32
In general, small intestinal involvement and
malabsorption are likely to contribute to the
higher prevalence of osteoporosis in Crohn’s
disease when localised in the small intestine,
compared to ulcerative colitis. The mechanism
of osteopaenia caused by the inflammatory
process is unclear. Various cytokine abnormali-
ties have been described in Crohn’s disease,33
which may stimulate bone resorption.34 35 Our
results showed a negative relation between the
bone resorption marker hydroxyproline and
BMD, and no relation between bone formation
markers and BMD. An increase in bone
resorption might account for a decrease in
BMD in these patients. Biphosphonates inhibit
bone resorption.36 Therefore, biphosphonates
might be appropriate therapy to reduce bone
loss. However, there is only limited experience
of the use of biphosphonates in children and
adolescents.37 Band-like metaphyseal sclerosis
and concentric epiphyseal and apophyseal
sclerosis have been described in children
treated with biphosphonates.38
Steroid therapy had a significant negative
correlation with lumbar spine BMD and in the
longitudinal data with the change in BMD of
lumbar spine as well as of total body. Some
studies reported a relation between corticoster-
oid use and BMD in patients with chronic
inflammatory bowel disease1 10 39 40 and others
did not.5 Corticosteroids are known to have a
negative influence on BMD, especially of
trabecular bone.41 Corticosteroids inhibit the
inflammatory process in the intestine. Since the
inflammatory process itself and malabsorption
as a consequence of the inflammation may also
negatively influence BMD, the eVect of corti-
costeroids on BMD is complex in patients with
IBD. Furthermore, corticosteroids are used
more often in patients with small bowel disease
and in more severe types of inflammation.
IBD is characterised by a pattern of exacer-
bations of disease activity of variable severity
interspersed with remissions. The variability of
the disease might be the reason that we did not
find a relation between the duration of the dis-
ease and BMD.
Figure 2 (A) Relation between lean tissue mass measured
by DXA and lean body mass measured by BIA. The
continuous line represents the regression line. (B) DiVerence
between lean tissue mass by DXA and lean body mass by
BIA against the mean for the two methods. LBM, lean
body mass; LTM, lean tissue mass.
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Body mass index, lean tissue mass, and fat
mass were decreased which may be related to
the fact that a high proportion of the patients
had an insuYcient caloric intake. A low caloric
intake has been reported before in patients with
IBD.32 42 43 Twenty two per cent of the children
of the present study had a low IGF-I, which
may be caused by undernutrition.44 The
findings are in agreement with findings of Kir-
schner and Sutton42 and Thomas et al,43 who
reported low serum IGF-I levels in children
with IBD. They showed an increase in IGF-I
following an increase of energy intake. A higher
body mass index, a parameter of the nutritional
status, was related to a higher BMD, which is
also found in adults.1 5 Nutritional recommen-
dations have been shown to reverse growth
impairment32 42 43 and will be beneficial for
bone mineralisation. Lean tissue mass SDS
correlated positively with lumbar spine and
total body BMD SDS. Increased lean tissue
mass, and thereby muscle mass, may be related
to more physical activity which may increase
BMD.
Vitamin D deficiency may play a role in the
pathogenic process of bone loss. Subnormal
serum 25-hydroxyvitamin D levels have been
reported in patients with chronic IBD.30 45 Ten
per cent of the patients of the present study had
decreased vitamin D levels. In a study of 150
adult patients with IBD no association was
found between low BMD and low serum levels
of 25-hydroxyvitamin D or elevated parathy-
roid hormone levels.30 However, vitamin D
might be of benefit in the treatment of
osteopaenia in these patients especially during
corticosteroid therapy. Sambrook et al 46
showed that treatment with calcium and calci-
triol could prevent corticosteroid induced bone
loss of the lumbar spine. In the present study a
selected group was treated with calcium and
vitamin D and may have benefited from this
treatment. Placebo controlled studies in chil-
dren with IBD are needed to evaluate the effect
of treatment with calcium and vitamin D on
BMD in these patients.
Delay in skeletal maturation and puberty
had a significant negative correlation with
BMD. However, the decrease in BMD could
not be explained by the retardation in bone
maturation. BMD SDS calculated for bone age
was also reduced. The delay in BMD might
catch up at a later age. The improvement in
BMDmay not be complete as shown in a study
of BMD of men with late puberty.47 Adult men
who had late puberty had a lower BMD than
men who had a normal timing of puberty.
The correlation between lean tissue mass
measured by DXA and lean body mass
measured by BIA was high. However, the lim-
its of agreement (−4.0 to 5.9 kg) were wider
than those found in healthy children (−2.0 to
3.9 kg).18 The diVerence between BIA lean
body mass and DXA lean tissue mass was
smaller than the diVerence between BIA lean
body mass and DXA lean body mass, which
includes bone mass. If BIA fat mass is
calculated as weight minus BIA lean body
mass, BIA fat mass is overestimated if DXA is
taken as the standard. In previous studies,
DXA was shown to be an accurate method of
measuring soft tissue composition by cross
calibration with chemical analysis after post-
mortem homogenisation.48 49 However, the
advantage of BIA is that it is cheap, quick, and
uses portable equipment.
From this study, it can be concluded that the
mean bone mineral density of children with
IBD was lower than reference values. Osteo-
paenia appears to be more common in children
with Crohn’s disease than in children with
ulcerative colitis. Corticosteroid therapy and
nutritional status are determinants of BMD in
these patients. Long term longitudinal studies
are needed to investigate whether these chil-
dren will attain a normal peak bone mass, and
they may benefit from calcium and vitamin D
supplementation or other therapies.
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